Evaluation of Programmed Death Ligand 1 (<i>PD-L1</i>) Gene Amplification and Response to Nivolumab Monotherapy in Non–small Cell Lung Cancer
Yusuke Inoue(Hamamatsu University School of Medicine), Takafumi Suda(Hamamatsu University School of Medicine)
Cited by 35
Related Papers
Prognostic impact of CD73 and A2A adenosine receptor expression in non-small-cell lung cancer
|Oncotarget|2017|173
Increased serum cholesterol and long-chain fatty acid levels are associated with the efficacy of nivolumab in patients with non-small cell lung cancer
|Cancer Immunology Immunotherapy|2021|44